NewGenIvf Group Limited (NASDAQ:NIVF – Get Free Report) saw a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 91,719 shares, a decline of 46.6% from the August 15th total of 171,641 shares. Based on an average daily volume of 672,683 shares, the short-interest ratio is currently 0.1 days. Currently, 6.4% of the shares of the stock are short sold.
Analysts Set New Price Targets
Several equities analysts recently issued reports on NIVF shares. Wall Street Zen raised shares of NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of NewGenIvf Group in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.
View Our Latest Stock Analysis on NIVF
Insider Buying and Selling at NewGenIvf Group
NewGenIvf Group Trading Down 7.1%
Shares of NIVF stock traded down $0.06 during mid-day trading on Thursday, hitting $0.73. 37,019 shares of the stock were exchanged, compared to its average volume of 281,813. NewGenIvf Group has a 52-week low of $0.71 and a 52-week high of $1,539.00. The company has a current ratio of 3.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.16. The firm has a fifty day moving average of $2.17 and a 200 day moving average of $9.17.
NewGenIvf Group Company Profile
NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.
NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.
See Also
- Five stocks we like better than NewGenIvf Group
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for NewGenIvf Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewGenIvf Group and related companies with MarketBeat.com's FREE daily email newsletter.
